{"product_id":"afmd-vrio-analysis","title":"Affimed N.V. (AFMD): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs Affimed N.V. (AFMD) truly positioned for sustainable success? This VRIO analysis cuts straight to the core, distilling whether its current resources offer a fleeting edge or a durable competitive advantage based on Value, Rarity, Inimitability, and Organization. Discover the critical findings that determine Affimed N.V. (AFMD)'s future market strength and strategic viability right below.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAffimed N.V. (AFMD) - VRIO Analysis: First Core Capabilities \/ Resources: ROCK® Platform Technology\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at the core engine of Affimed N.V. - the ROCK® Platform Technology - and trying to figure out if it was a sustainable moat or just a very expensive engine that ran out of fuel. Honestly, the answer is complex, but the final outcome is clear: the technology had promise, but the financial structure supporting it did not last through \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3 class=\"h3_crct\"\u003eValue: Enabling Targeted Tumor Killing\u003c\/h3\u003e\n\u003cp\u003eThe platform’s value proposition was solid: it enabled the predictable generation of customized Innate Cell Engager (ICE®) molecules designed for tumor-targeted killing. This is a big deal because it aims to harness the patient’s own innate immune cells, like Natural Killer (NK) cells, to fight cancer more effectively. Think of it as building a highly specific key (the ICE® molecule) for a very stubborn lock (the tumor).\u003c\/p\u003e\n\u003cp\u003eFor example, the AFM24 program, built on this tech, showed an Objective Response Rate (ORR) in certain Non-Small Cell Lung Cancer (NSCLC) cohorts, with median Progression Free Survival (PFS) reported around \u003cstrong\u003e5.9 months\u003c\/strong\u003e based on data presented in late 2024 for a data cut in November 2024. That level of activity in heavily pre-treated patients demonstrates inherent value.\u003c\/p\u003e\n\n\u003ch3 class=\"h3_crct\"\u003eRarity: A Unique Design Approach\u003c\/h3\u003e\n\u003cp\u003eThe specific design and engineering of the ROCK® platform to engage innate immune cells is relatively unique in the crowded field of immuno-oncology. It’s not just another T-cell engager; it’s focused on NK cells, which is a distinct approach. This proprietary nature made it rare, at least in terms of its specific molecular architecture and engineering pathway.\u003c\/p\u003e\n\n\u003ch3 class=\"h3_crct\"\u003eImitability: Specialized Expertise Required\u003c\/h3\u003e\n\u003cp\u003eReplicating this technology would be moderately difficult. It requires deep, specialized protein engineering expertise and years of iterative development - the kind of institutional knowledge that doesn't transfer easily. It’s not something a competitor could just buy off the shelf; they’d need to hire away key personnel and spend significant time in the lab refining the process.\u003c\/p\u003e\n\n\u003ch3 class=\"h3_crct\"\u003eOrganization: The Fatal Flaw\u003c\/h3\u003e\n\u003cp\u003eHere’s where the story turns south. The organization was definitely focused on leveraging this platform for multiple pipeline assets, including AFM13, AFM24, and AFM28. However, the company ultimately failed to secure the long-term financial viability needed to see these assets through. As of September 30, 2024, the cash position was only \u003cstrong\u003e€24.1 million\u003c\/strong\u003e, which management projected would finance operations into \u003cstrong\u003eQ4 of 2025\u003c\/strong\u003e. That runway proved insufficient.\u003c\/p\u003e\n\u003cp\u003eThe organization’s inability to secure further funding or partnerships to extend operations past that point is the critical failure point.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFiled for insolvency on \u003cstrong\u003eMay 13, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNasdaq trading suspended on \u003cstrong\u003eMay 20, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eDelisting effective \u003cstrong\u003eMay 21, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3 class=\"h3_crct\"\u003eCompetitive Advantage: Temporary at Best\u003c\/h3\u003e\n\u003cp\u003eThe platform’s potential was high, suggesting a temporary competitive advantage based on its technical superiority. But a competitive advantage is only sustained if the company can keep the lights on and keep developing the product. Since the organization could not sustain operations past the projected \u003cstrong\u003eQ4 2025\u003c\/strong\u003e timeline, the advantage was, by definition, temporary.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math: a cash runway into \u003cstrong\u003eQ4 2025\u003c\/strong\u003e, followed by insolvency in \u003cstrong\u003eMay 2025\u003c\/strong\u003e, shows the financial planning or fundraising efforts fell short of the required timeline for platform maturation.\u003c\/p\u003e\n\n\u003cp\u003eThe VRIO assessment for the ROCK® Platform Technology looks like this:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Dimension\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003cth\u003eImplication for Advantage\u003c\/th\u003e\n\u003cth\u003eKey Data Point (2025 Context)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eCompetitive Parity\/Potential Advantage\u003c\/td\u003e\n\u003ctd\u003eReported ORR in NSCLC cohorts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n\u003ctd\u003eProprietary ICE® molecule design\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eDifficult\u003c\/td\u003e\n\u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n\u003ctd\u003eRequires specialized protein engineering expertise\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eNo\u003c\/td\u003e\n\u003ctd\u003eCompetitive Disadvantage\u003c\/td\u003e\n\u003ctd\u003eInsolvency filed \u003cstrong\u003eMay 13, 2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eWhat this estimate hides is the value of the underlying intellectual property, which may still be licensed or sold, but the operational advantage tied to Affimed N.V. itself is gone.\u003c\/p\u003e\n\n\u003cp\u003eFinance: draft a memo detailing the IP asset valuation post-insolvency filing by next Tuesday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAffimed N.V. (AFMD) - VRIO Analysis: Second Core Capabilities \/ Resources: Innate Cell Engager (ICE®) Molecule Design\n\u003c\/h2\u003e\n\u003cp\u003eThe ICE® Molecule Design capability is assessed based on the framework of Value, Rarity, Imitability, and Organization (VRIO).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: Creates molecules that specifically target CD16A on innate immune cells to destroy tumor cells.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe platform demonstrated specific clinical efficacy in target indications. For instance, lead asset AFM13 showed an 94% Overall Response Rate (ORR) and 71% Complete Response (CR) in a specific patient cohort related to CD30+ lymphomas. The platform has treated nearly 400 patients with proprietary ICE® molecules to date.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: The specific ICE® format, which leverages innate immunity, is a distinct approach compared to standard CAR-T or bispecifics.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe approach is distinct due to its focus on CD16A engagement of innate immune cells. The pipeline includes multiple assets leveraging this core technology:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAFM13 (CD30\/CD16A)\u003c\/li\u003e\n\u003cli\u003eAFM24 (EGFR\/CD16A)\u003c\/li\u003e\n\u003cli\u003eAFM28 (CD123\/CD16A)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: High initial barrier, but competitors can develop similar multi-specific formats over time.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe initial development of the proprietary format created a time-based barrier. The company's pipeline progression reflects this investment in the technology:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eTarget Indication\/Status Highlight\u003c\/th\u003e\n\u003cth\u003eData Point\/Status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAFM13\u003c\/td\u003e\n\u003ctd\u003eCD30+ Lymphomas (cHL\/PTCL)\u003c\/td\u003e\n\u003ctd\u003eCompleted Phase II clinical trial for CD30-positive lymphoma.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAFM24\u003c\/td\u003e\n\u003ctd\u003eNSCLC (EGFRwt) Combination\u003c\/td\u003e\n\u003ctd\u003eEnrollment completed for the combination cohort with atezolizumab as of Q3 2024.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAFM28\u003c\/td\u003e\n\u003ctd\u003er\/r AML (CD123-positive)\u003c\/td\u003e\n\u003ctd\u003eCleared first dose cohort without dose limiting toxicities in monotherapy dose escalation study (as of Q1 2023).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: The company treated ICE® generation as a core competency, applying it across its pipeline.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOrganizational focus is evidenced by sustained investment in R\u0026amp;D to advance the pipeline. Research and development expenses for the quarter ended March 31, 2023, were €29.5 million, an increase of 60.7% from the prior year, primarily due to development costs for AFM13 and AFM24 programs.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Temporary; demonstrated clinical proof of concept, but not sufficient to prevent insolvency.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eClinical proof of concept was demonstrated across hematological and solid tumors. However, financial stability was challenged:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAs of September 30, 2024, cash, cash equivalents and investments totaled €24.1 million.\u003c\/li\u003e\n\u003cli\u003eThe projected cash runway, based on operating plans, extended into Q4 2025.\u003c\/li\u003e\n\u003cli\u003eNet loss for Q3 2024 was €15.1 million, or €0.94 loss per common share.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAffimed N.V. (AFMD) - VRIO Analysis: Third Core Capabilities \/ Resources: AFM13 (Lead Clinical Asset)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Demonstrated unprecedented efficacy against CD30-positive lymphomas in clinical settings.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOverall Response Rate (ORR) of \u003cstrong\u003e92.9%\u003c\/strong\u003e in 42 heavily pretreated patients with relapsed\/refractory lymphoma treated with AFM13-NK combination therapy.\u003c\/li\u003e\n\u003cli\u003eComplete Response (CR) rate of \u003cstrong\u003e66.7%\u003c\/strong\u003e in the same patient group.\u003c\/li\u003e\n\u003cli\u003eIn patients with Hodgkin lymphoma (n=27), ORR was \u003cstrong\u003e97.3%\u003c\/strong\u003e and CR was \u003cstrong\u003e73%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePatients were refractory to brentuximab vedotin and anti-PD1 immune checkpoint inhibitors.\u003c\/li\u003e\n\u003cli\u003eTwo-year Event-Free Survival (EFS) rate of \u003cstrong\u003e26.2%\u003c\/strong\u003e and Overall Survival (OS) rate of \u003cstrong\u003e76.2%\u003c\/strong\u003e at a median follow-up of \u003cstrong\u003e20 months\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High, as it showed strong activity in a heavily pre-treated population.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMedian of \u003cstrong\u003e7\u003c\/strong\u003e prior lines of therapy for patients in the Phase 1 trial (NCT04074746).\u003c\/li\u003e\n\u003cli\u003eMedian age of trial participants was \u003cstrong\u003e43\u003c\/strong\u003e years.\u003c\/li\u003e\n\u003cli\u003eIn the LuminICE-203 dose-finding part, median prior treatment lines was \u003cstrong\u003e4.5\u003c\/strong\u003e (range 2–13), including previous stem cell transplant in \u003cstrong\u003e58%\u003c\/strong\u003e of patients.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAFM13-NK (N=42)\u003c\/th\u003e\n\u003cth\u003eHodgkin Lymphoma Subset (n=27)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverall Response Rate (ORR)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e92.9%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e97.3%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eComplete Response Rate (CR)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e66.7%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e73%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2-Year Event-Free Survival (EFS)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e26.2%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2-Year Overall Survival (OS)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e76.2%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low for the specific molecule, but the mechanism is imitable by other ICE® developers.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAFM13 is a bispecific antibody targeting CD16A on NK cells and CD30 on lymphoma cells.\u003c\/li\u003e\n\u003cli\u003eThe mechanism involves activating NK cells to kill CD30+ cells.\u003c\/li\u003e\n\u003cli\u003eThe technology involves pre-complexing NK cells with AFM13 to give them CAR-like properties against CD30-positive cells.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Organization was focused on advancing AFM13, including combination studies with allogeneic NK cells.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe development included an Investigator Sponsored Trial (IST) led by MD Anderson Cancer Center (AFM13-104).\u003c\/li\u003e\n\u003cli\u003eThe company was on track to submit an IND for the combination trial (AFM13 with Artiva's AB-101 NK cells) in the first half of 2023.\u003c\/li\u003e\n\u003cli\u003ePhase 2 trial LuminICE-203 (NCT05883449) evaluates AFM13 in combination with AlloNK (AB-101).\u003c\/li\u003e\n\u003cli\u003eAs of June 30, 2024, cash, cash equivalents and investments were \u003cstrong\u003e€34.4 million\u003c\/strong\u003e, with cash-runway projected into H2 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; strong data existed, but it was not monetized or advanced to late-stage success before the May 2025 filing.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eData published in Nature Medicine in April 2025 showed high efficacy.\u003c\/li\u003e\n\u003cli\u003eAs of Q3 2024, cash balance was \u003cstrong\u003e€24.1 million\u003c\/strong\u003e, with operations expected into Q4 2025.\u003c\/li\u003e\n\u003cli\u003eThe company was anticipating decisions regarding taking the doublet into a registration-directed trial by early, probably first quarter, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAffimed N.V. (AFMD) - VRIO Analysis: Fourth Core Capabilities \/ Resources: AFM24 (Clinical Asset)\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nAFM24 demonstrated activity in heavily pretreated populations:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eIn EGFR mutant (EGFRmut) NSCLC patients (17 in PPS) combined with atezolizumab, an Overall Response Rate (ORR) of 24% (1 Complete Response (CR), 3 Partial Responses (PRs)) was observed.\u003c\/li\u003e\n\u003cli\u003eDisease Control Rate (DCR) was 71% in the EGFRmut NSCLC cohort.\u003c\/li\u003e\n\u003cli\u003eMedian Progression-Free Survival (PFS) was 5.6 months in the EGFRmut NSCLC cohort.\u003c\/li\u003e\n\u003cli\u003e29% (5) of EGFRmut NSCLC patients were on treatment for over 10 months.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eIndication (AFM24 + Atezolizumab)\u003c\/th\u003e\n\u003cth\u003eN (PPS)\u003c\/th\u003e\n\u003cth\u003eORR\u003c\/th\u003e\n\u003cth\u003eDCR\u003c\/th\u003e\n\u003cth\u003eMedian PFS\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNSCLC EGFR wild-type (EGFRwt)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e33\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e21%\u003c\/strong\u003e (7 responses: 1 CR, 5 PRs, 1 unconfirmed PR)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e76%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5.6 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNSCLC EGFR mutant (EGFRmut)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e17\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e24%\u003c\/strong\u003e (1 CR, 3 PRs)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e71%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5.6 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\nIn a separate gastric cancer study, one patient with signet-ring cell mGC achieved a Partial Response (PR) lasting ~8 months and continued for more than 14 months in total.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe asset is a bispecific, tetravalent Innate Cell Engager (ICE®) binding CD16A and EGFR. In the Phase 1, 4 confirmed responses (1 CR, 3 PRs) were seen in 15 heavily pre-treated patients with AFM24 monotherapy. The Recommended Phase 2 Dose (RP2D) was established at 480 mg weekly.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe FDA granted Fast Track designation to the combination for NSCLC EGFRwt after progression on PD(L)1 and platinum-based chemotherapy.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe company was actively evaluating AFM24 in the AFM24-102 trial (NCT05109442).\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAs of September 30, 2024, cash, cash equivalents, and investments totaled €24.1 million.\u003c\/li\u003e\n\u003cli\u003eCash runway was projected into Q4 2025.\u003c\/li\u003e\n\u003cli\u003eResearch and development expenses for Q3 2024 were €10.1 million, down from €21.5 million in Q3 2023.\u003c\/li\u003e\n\u003cli\u003eNet loss for Q3 2024 was €15.1 million.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe NSCLC EGFRwt cohort had 43 patients in the Full Analysis Set (FAS) as of November 14, 2024. Future development planned to use a 720 mg weekly dose, based on exposure-response analysis.\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAffimed N.V. (AFMD) - VRIO Analysis: Fifth Core Capabilities \/ Resources: AFM28 (Clinical Asset)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Presented a differentiated profile in vitro for treating Acute Myeloid Leukemia (AML).\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eInduction of tumor cell killing \u003cem\u003ein vitro\u003c\/em\u003e against CD123-positive cells irrespective of mutational status.\u003c\/li\u003e\n\u003cli\u003eDemonstrated ability to destroy CD123-positive tumor cell lines and primary leukemic cells via antibody-dependent cell-mediated cytotoxicity (ADCC).\u003c\/li\u003e\n\u003cli\u003eDepletion of CD123-positive leukemic stem cells and progenitor cells while sparing healthy cells in ex vivo bone marrow samples.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; AML is a crowded space, but a differentiated ICE® profile offers a niche advantage.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAFM28 is a bispecific, tetravalent innate cell engager (ICE®) targeting CD123 and CD16A.\u003c\/li\u003e\n\u003cli\u003eTargeting CD123 is acknowledged to hold significant untapped promise in developing better AML therapies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; requires specific \u003cem\u003ein vitro\u003c\/em\u003e and early clinical validation to prove superiority.\u003c\/p\u003e\n\u003cp\u003eThe asset's imitable barrier is based on the proprietary ROCK® platform technology and the specific binding profile of the molecule.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eClinical Metric\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eStudy Population Size (Reported)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e29\u003c\/strong\u003e heavily pretreated R\/R AML patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDose Levels Tested\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e6\u003c\/strong\u003e dose levels\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDose Range\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e25 mg\u003c\/strong\u003e to \u003cstrong\u003e300 mg\u003c\/strong\u003e weekly\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eComposite Complete Remission Rate (CRcR) at 300 mg\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e40%\u003c\/strong\u003e (1 CR and 3 CRi in 10 evaluable patients)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian Prior Treatment Lines\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eTwo\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients with Unfavorable Risk Profile (ELN2022)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e86%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The company was running a Phase 1 dose-escalation study for AFM28.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe study is the first-in-human Phase 1, open-label, non-randomized multiple ascending dose escalation study (AFM28-101).\u003c\/li\u003e\n\u003cli\u003eThe goal of dose escalation is to establish the Maximum Tolerated Dose (MTD) and\/or one or more Recommended Phase 2 Doses (RP2D).\u003c\/li\u003e\n\u003cli\u003eEnrollment was completed in the sixth and final cohort as of June 2024.\u003c\/li\u003e\n\u003cli\u003eAs of \u003cstrong\u003eSeptember 30, 2024\u003c\/strong\u003e, cash, cash equivalents, and investments totaled \u003cstrong\u003e€24.1 million\u003c\/strong\u003e, with a projected cash runway into \u003cstrong\u003eQ4 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eResearch and development expenses for the year ended \u003cstrong\u003eDecember 31, 2023\u003c\/strong\u003e, were \u003cstrong\u003e€95.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Not sustained; this asset was in the earliest clinical stage and required substantial investment.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAffimed N.V. (AFMD) - VRIO Analysis: Sixth Core Capabilities \/ Resources: Established Clinical Proof of Concept Data\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Data validating the ICE® strategy across both hematologic and solid tumors with a strong safety profile.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAFM13 combination with AlloNK® (AB-101) in treatment-refractory Hodgkin Lymphoma (HL) patients showed an 85.7% ORR with 4 CRs in the first 7 patients.\u003c\/li\u003e\n\u003cli\u003eAFM13 in combination with cord blood-derived NK cells (cbNK) in CD30-positive relapsed or refractory (r\/r) lymphomas achieved a 94.4% objective response rate and a 72.2% complete response rate in 36 patients treated at the recommended Phase 2 dose level (RP2D).\u003c\/li\u003e\n\u003cli\u003eThe AFM13\/cbNK regimen demonstrated a good safety and tolerability profile with no cases of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS) or graft versus host disease (GVHD) of any grade.\u003c\/li\u003e\n\u003cli\u003eAFM24 combination with atezolizumab in 17 EGFR wild-type (EGFRwt) non-small cell lung cancer (NSCLC) patients who failed chemotherapy and PD-1\/L1 treatment showed a 71% Disease Control Rate (DCR).\u003c\/li\u003e\n\u003cli\u003eAFM28 monotherapy in a Phase 1 dose-escalation study reported a 33% CR\/CRi rate in 6 patients treated at dose level 6 (300mg weekly).\u003c\/li\u003e\n\u003cli\u003eNearly 400 patients have been treated with proprietary ICE® molecules to date.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High; having clinical proof of concept for all three innate cell engagers is a significant de-risking milestone.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eIndication Type\u003c\/th\u003e\n\u003cth\u003eKey Efficacy Metric\u003c\/th\u003e\n\u003cth\u003eNumber of Patients (N)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAFM13\u003c\/td\u003e\n\u003ctd\u003eHematologic (R\/R HL\/NHL)\u003c\/td\u003e\n\u003ctd\u003e94.4% ORR\u003c\/td\u003e\n\u003ctd\u003e36 (at RP2D)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAFM24\u003c\/td\u003e\n\u003ctd\u003eSolid Tumor (NSCLC)\u003c\/td\u003e\n\u003ctd\u003e71% DCR\u003c\/td\u003e\n\u003ctd\u003e17 (EGFRwt)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAFM28\u003c\/td\u003e\n\u003ctd\u003eHematologic (R\/R AML)\u003c\/td\u003e\n\u003ctd\u003e33% CR\/CRi rate\u003c\/td\u003e\n\u003ctd\u003e6 (Dose Level 6)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; this specific dataset is proprietary and cannot be replicated without running the same trials.\u003c\/p\u003e\n\u003cp\u003eThe proprietary nature of the ROCK® platform which predictably generates customized ICE® molecules is the source of this low imitability.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Management used this data to attract potential partners and justify continued operations.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRevenue from collaborations, such as the one with Genentech, included $96.0 million in initial upfront and committed funding.\u003c\/li\u003e\n\u003cli\u003eA partnership with Roivant Sciences Ltd. provided $60 million in upfront consideration.\u003c\/li\u003e\n\u003cli\u003eAs of September 30, 2024, the cash position was €24.1 million, projecting a cash runway into Q4 2025.\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D expenses for Q3 2024 were €10.1 million.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; this data was the primary source of near-term value but was insufficient to secure the necessary financing.\u003c\/p\u003e\n\u003cp\u003eThe company filed for the opening of insolvency proceedings on May 13, 2025, leading to a Nasdaq delisting on May 20, 2025.\u003c\/p\u003e\n\u003cp\u003eThe stock traded around $0.18 per share as of May 2025.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAffimed N.V. (AFMD) - VRIO Analysis: Seventh Core Capabilities \/ Resources: Intellectual Property (IP) Portfolio\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides legal exclusivity over the ROCK® platform, ICE® designs, and specific drug candidates.\u003c\/p\u003e\n\u003cp\u003eThe scope and protection afforded by the IP portfolio can be quantified by the following metrics:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eContext\/Date\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent Families Protecting Technology\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e48\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore Immunotherapy Patent Families\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e17\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGranted Patents (Alternative Count)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e37\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUnspecified Date\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch and Development Expenditure\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$62.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High; patent thickets around novel modalities are crucial barriers to entry in biotech.\u003c\/p\u003e\n\u003cp\u003eThe company's proprietary platform is described as enabling the generation of first-in-class tetravalent, multi-specific immune cell engagers.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; patents are legally protected and difficult to design around without infringement.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The legal and R\u0026amp;D teams worked to maintain and expand the patent estate.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eR\u0026amp;D Personnel constituted \u003cstrong\u003e62%\u003c\/strong\u003e of the total workforce of \u003cstrong\u003e168\u003c\/strong\u003e employees.\u003c\/li\u003e\n\u003cli\u003eThe Research and Development expenditure in 2022 was \u003cstrong\u003e$62.3 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe authorized share capital of the company is \u003cstrong\u003eEUR 7,500,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAs of June 30, 2024, the issued share capital was \u003cstrong\u003e€1,568,076.91\u003c\/strong\u003e, divided into \u003cstrong\u003e15,680,769.1\u003c\/strong\u003e common shares.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained (in theory); the IP remains valuable even post-insolvency, potentially for licensees or acquirers.\u003c\/p\u003e\n\u003cp\u003eThe market capitalization as of Q3 2023 was reported as \u003cstrong\u003e$87.6 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAffimed N.V. (AFMD) - VRIO Analysis: Eighth Core Capabilities \/ Resources: Strategic Partnership Framework\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Ability to generate non-dilutive funding and share development risk through collaborations with larger pharma.\u003c\/p\u003e\n\u003cp\u003eThe strategic partnership framework aimed to secure significant non-dilutive capital. For instance, the collaboration with Genentech provided $96 million in initial upfront and committed funding as of October 31, 2018. The collaboration with Roivant Sciences Ltd. resulted in $60 million in upfront consideration, comprising $40 million in cash and $20 million of common shares.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePartnership\u003c\/th\u003e\n\u003cth\u003eUpfront\/Committed Funding\u003c\/th\u003e\n\u003cth\u003eTotal Potential Milestones\/Other\u003c\/th\u003e\n\u003cth\u003eKey Metric\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenentech Inc.\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$96 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp to an additional \u003cstrong\u003e$5.0 billion\u003c\/strong\u003e plus royalties\u003c\/td\u003e\n\u003ctd\u003eEffective October 2018\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoivant Sciences Ltd.\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$60 million\u003c\/strong\u003e (\u003cstrong\u003e$40 million\u003c\/strong\u003e cash, \u003cstrong\u003e$20 million\u003c\/strong\u003e shares)\u003c\/td\u003e\n\u003ctd\u003eUp to an additional \u003cstrong\u003e$5.0 billion\u003c\/strong\u003e plus tiered royalties\u003c\/td\u003e\n\u003ctd\u003eAnnounced November 9, 2020\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eArtiva Biotherapeutics\u003c\/td\u003e\n\u003ctd\u003eCost sharing structure\u003c\/td\u003e\n\u003ctd\u003eAcitamig showed ORR above \u003cstrong\u003e80%\u003c\/strong\u003e in one context\u003c\/td\u003e\n\u003ctd\u003eMentioned March 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; many biotechs seek partnerships, but Affimed's unique platform made its partnership potential distinct.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; the specific relationships and deal structures are unique to the company's history.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The CEO explicitly stated efforts to seek collaborations to drive success.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCEO Adi Hoess described the Genentech partnership as a '\u003cstrong\u003etransformational accomplishment for Affimed\u003c\/strong\u003e.'\u003c\/li\u003e\n\u003cli\u003eCEO Sean Nilan highlighted that pipeline prioritization was driven by investor interest and commercial potential, given the company's \u003cstrong\u003elimited cash runway\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAs of Q3 2024, the cash balance was \u003cstrong\u003e€24.1 million\u003c\/strong\u003e, with prior expectations to finance operations into \u003cstrong\u003eQ4 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; the ability to partner was present, but the execution to secure a deal that averted insolvency failed.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company filed for insolvency proceedings on \u003cstrong\u003eMay 13, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash and cash equivalents were \u003cstrong\u003e€72 million\u003c\/strong\u003e on December 31, 2023.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAffimed N.V. (AFMD) - VRIO Analysis: Ninth Core Capabilities \/ Resources: Experienced Leadership Team (Pre-Insolvency)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Expertise in leading and expanding biotech companies, including navigating clinical development and financing.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; experienced biotech leadership is available, but finding leaders with specific platform success is rarer.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; specific leadership chemistry and historical success are hard to replicate quickly.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The team was focused on a strategic transformation and refining focus on clinical priorities.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe January 2024 strategic restructuring led to a reduction of headcount by approximately \u003cstrong\u003e50%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTermination expenses incurred during the nine months ended September 30, 2024, totaled \u003cstrong\u003e€1.6 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAs of September 30, 2024, the accumulated deficit was \u003cstrong\u003e€585.9 million\u003c\/strong\u003e, with total net equity of \u003cstrong\u003e€17.2 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ3 2024 Value\u003c\/td\u003e\n\u003ctd\u003eComparative Period\/Date\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€0.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003evs €2.0 million (Q3 2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€15.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003evs €24.4 million (Q3 2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€10.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003evs €21.5 million (Q3 2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€24.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRunway Projection\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eQ4 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBased on September 30, 2024 plans\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Not sustained; the team could not organize the company to overcome the financial challenges leading to the May 13, 2025 filing for insolvency proceedings in Mannheim, Germany, due to insufficient capital.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFinance:\u003c\/strong\u003e The company announced the filing for insolvency proceedings on May 13, 2025, after fundraising efforts fell short, leading to a determination of overindebtedness. The stock price fell to $0.13 per share, with the stock having fallen \u003cstrong\u003e97%\u003c\/strong\u003e over the past year, and the market capitalization dropped to \u003cstrong\u003e$2.2 million\u003c\/strong\u003e following the filing news.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516107776149,"sku":"afmd-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/afmd-vrio-analysis.png?v=1740142491","url":"https:\/\/dcf-model.com\/es\/products\/afmd-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}